The companies have been collaborating on the development of Kryptos' molecular tests, and Osang led Kryptos' $10 million financing round in 2024.
The Amsterdam-based company recently received IVDR certification for other tests including one for phenylketonuria.
CMS officials said they have implemented national controls and sought repayment from dozens of healthcare providers and suppliers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback